Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora

This study has been completed.
Sponsor:
Collaborator:
St. Joseph's Health Care Foundation
Information provided by (Responsible Party):
Phil Hooper, Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT01577342
First received: April 11, 2012
Last updated: April 12, 2012
Last verified: April 2012
  Purpose

Ranibizumab (Lucentis) is currently the best treatment for wet Age-Related Macular Degeneration (AMD). To work, the drug must be injected by means of an intravitreal injection (IVT) into the vitreous (jelly-like material) cavity in the back of the eye, repeatedly at intervals ranging from one to several months. Endophthalmitis is a rare but devastating infection of the eye that occurs in approximately 0.2% of patients after IVT injection. Many ophthalmologists ask patients to use antibiotic eye drops after IVT injection in the hope that this may reduce the risk of endophthalmitis. There is no proof that this happens and there is a possible risk that repeated exposure to the same antibiotic may cause antibiotic resistance organisms (bacteria) to develop over time.

The investigators hypothesize that repeated exposure to antibiotic during the initial stages of treatment for AMD will result in a progressive shift in the conjunctival flora with an increasing number of antibiotic resistant organisms appearing over time. If this is demonstrated, changes to the prevailing treatment approach will be needed to reduce the long term risk of a patient developing antibiotic resistant endophthalmitis during treatment.


Condition Intervention
Age-Related Macular Degeneration
Drug: Moxifloxacin 0.5%

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora

Resource links provided by NLM:


Further study details as provided by Lawson Health Research Institute:

Primary Outcome Measures:
  • Incidence of antibiotic resistant organisms [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]

    Conjunctival culture will be obtained in the designated "study" eye prior to the first intravitreal injection in de novo AMD patients and will be repeated prior to the next 3 injections.

    Susceptibility or resistance of the ocular surface flora to Moxifloxicin will be assessed by standard micro analysis.



Enrollment: 56
Study Start Date: November 2010
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Moxifloxacin 0.5%
1 drop four times daily for 3 days in affected eye post intravitreal injection
Drug: Moxifloxacin 0.5%
1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
Other Name: Vigamox
No Intervention: No antibiotic use

Detailed Description:

Intraocular injection of a VEGF inhibitor on a repeated basis has become the standard of care for the treatment of Age-Related Macular Degeneration (AMD) following pivotal studies which demonstrated that vision could be stabilized in 90% of treated patients. Most patients require injection, on average, every two months indefinitely.

The incidence of intraocular infection (endophthalmitis) following intraocular injection is approximately 0.2%. Current injection protocols involve the use of topical poviodine prior to injection based on evidence that this significantly reduces the bacterial flora on the conjunctiva. Following injection there is often some reflux of vitreous fluid from the cavity of the eye into the subjunctival space. For this reason many Ophthalmologists have patients use topical antibiotics for 2-3 days post injection with the expectation that this may reduce the risk of infection as the eye is healing.

Ta et al have demonstrated that following a 3 day course of topical antibiotic the incidence of resistant strains of bacteria in the conjunctival sac does not significantly increase (159 patients).There are no longitudinal studies which examine the effects of repeated short term antibiotic exposure on the conjunctival flora over time.

This is a prospective, randomized, comparative study which will follow the conjunctival flora of patients undergoing induction treatment with a VEGF inhibitor for AMD. The incidence of resistant organisms in the group receiving antibiotics will be compared to that in a similar group who do not receive antibiotics. Following informed consent, patients will have a conjunctival swab taken by the treating Ophthalmologist after instillation of sterile topical anesthetic but before application of poviodine. The swabs will be cultured in thyoglycollate broth. Bacteria present and resistance to the antibiotic used will be identified. This process will be repeated each visit during the induction phase of treatment which consists of four sequential injections each a month apart.

Patients in the antibiotic arm will be asked to use topical Moxifloxacin drops 4 times a day for 3 days following injection. The control group will not receive antibiotics.

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • all patients undergoing their first ever injection to treat AMD and who are expected to continue treatment in London for at least the next 3 injections are potentially eligible.
  • able to provide Informed Consent.

Exclusion Criteria:

  • current contact lens use.
  • use of topical antibiotics in the study eye in the preceding 6 months.
  • patients in whom eye surgery in the study eye is anticipated in the next 4 months.
  • documented allergy to the drug or vehicle.
  • patients with active ocular, periocular or systemic infection.
  • immunosuppressed patients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01577342

Locations
Canada, Ontario
Ivey Eye Institute, St. Joseph's Health Care Centre
London, Ontario, Canada, N6A 4V2
Sponsors and Collaborators
Lawson Health Research Institute
St. Joseph's Health Care Foundation
Investigators
Principal Investigator: Philip L Hooper, MD, FRCSC Ivey Eye Institute, St. Joseph's Health Care Centre
  More Information

No publications provided

Responsible Party: Phil Hooper, Principal Investigator, Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT01577342     History of Changes
Other Study ID Numbers: R-10-458, 17354
Study First Received: April 11, 2012
Last Updated: April 12, 2012
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Anti-Bacterial Agents
Moxifloxacin
Antibiotics, Antitubercular
Norgestimate, ethinyl estradiol drug combination
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 14, 2014